Drugs / YSCH-01
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT07538128 | Jan 2025 → Nov 2026 expected | glioblastoma | Huashan Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT05180851 | Nov 2021 → May 2023 | breast cancer, cervical carcinoma, head and neck cancer, lung cancer +3 | Shanghai Fengxian District Central Hospital | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07307053 | Jan 2026 → Jan 2029 expected | high grade malignant neoplasm, metastatic neoplasm | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YSCH-01 | “OBJECTIVE: To evaluate the safety and preliminary efficacy of YSCH-01 (Recombinant L-IFN adenovirus) in subjects with advanced solid tumors.” PMID 38719544 ↗ May 2024 |
| Known as | Recombinant L-IFN adenovirus | “OBJECTIVE: To evaluate the safety and preliminary efficacy of YSCH-01 (Recombinant L-IFN adenovirus) in subjects with advanced solid tumors.” PMID 38719544 ↗ May 2024 |
| Route | Other | “Subjects were administered YSCH-01 injection via intratumoral injections.” PMID 38719544 ↗ May 2024 |